The EZH2 inhibitor tazemetostat, the first FDA-approved HMT inhibitor for cancer treatment, is currently one of the most investigated compounds in the clinical trial, with its anti-cancer properties established in preclinical studies [297,298]. The gene discussed is EZH2; the disease is cancer.